title: Prostaglandin E1 infusion compared with prostacyclin infusion in patients with refractory heart failure: effects on hemodynamics and neurohumoral variables.
abstract: Prostaglandin E1 or prostacyclin were randomly infused in 18 patients with severe chronic heart failure who did not respond to oral treatment. Maximally tolerated dosages of both agents increased cardiac index; however, only prostacyclin decreased mean arterial pressure and increased plasma norepinephrine significantly. Twelve hours after 50% peak dose reduction, atrial natriuretic peptide levels, right atrial pressure, mean pulmonary artery pressure, and mean arterial pressure continued to decrease with prostaglandin E1, whereas the increase in cardiac index was sustained; in contrast, at 50% prostacyclin dose reduction, cardiac index decreased toward baseline, suggesting that, with reduced dosages for chronic infusions, desired hemodynamic changes seem to be sustained with prostaglandin E1 only.
authors.affiliation: Department of Cardiology, University of Vienna, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Pacher
authors.forename: B
authors.initials: B
authors.lastname: Stanek
authors.forename: M
authors.initials: M
authors.lastname: Hülsmann
authors.forename: A
authors.initials: A
authors.lastname: Bojic
authors.forename: R
authors.initials: R
authors.lastname: Berger
authors.forename: B
authors.initials: B
authors.lastname: Frey
authors.forename: A
authors.initials: A
authors.lastname: Siegel
authors.forename: T
authors.initials: T
authors.lastname: Kos
authors.forename: E
authors.initials: E
authors.lastname: Ogris
authors.forename: M
authors.initials: M
authors.lastname: Grimm
authors.forename: G
authors.initials: G
authors.lastname: Laufer
mesh_terms: D000527:Alprostadil / Q000008:administration & dosage* / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1; D016232:Endothelins / Q000097:blood; D011464:Epoprostenol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000097:blood*; D011498:Protein Precursors / Q000097:blood; D011669:Pulmonary Wedge Pressure / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000959:Antihypertensive Agents; D019332:Endothelin-1; D016232:Endothelins; D018377:Neurotransmitter Agents; D011498:Protein Precursors; D014665:Vasodilator Agents; D009320:Atrial Natriuretic Factor; D011464:Epoprostenol; D000527:Alprostadil